Skip to content
TheChatArchiveThe Chat Archive
ClaudeClaude Opus 4.5· anthropicHugging Face Frontier Reasoning Traces

Provide a guideline-based approach to heart failure with reduced ejection fraction:…

  1. User

    Provide a guideline-based approach to heart failure with reduced ejection fraction: staging, diagnostics, GDMT with dosing/titration, device therapy, comorbidity management, decompensation protocols, and follow-up.

  2. Claude Assistant

    This is a comprehensive question about heart failure with reduced ejection fraction (HFrEF). I need to provide a detailed, guideline-based approach covering all the aspects mentioned. Let me organize this systematically based on current guidelines (ACC/AHA 2022, ESC 2023, and other relevant guidelines).

    Let me structure this response:

    1. Staging of HF
    2. Diagnostics
    3. GDMT with dosing/titration
    4. Device therapy
    5. Comorbidity management
    6. Decompensation protocols
    7. Follow-up

    Let me go through each section in detail:

    1. STAGING (ACC/AHA 2022)

    Stage A - At risk for HF

    • Patients with HTN, DM, CAD, obesity, metabolic syndrome, family history of cardiomyopathy, exposure to cardiotoxic agents
    • No structural heart disease or symptoms

    Stage B - Pre-HF

    • Structural heart disease (LVH, reduced EF, valvular disease, wall motion abnormalities)
    • Elevated filling pressures
    • No symptoms or signs of HF

    Stage C - Symptomatic HF

    • Structural heart disease with current or prior symptoms of HF

    Stage D - Advanced HF

    • Marked symptoms that interfere with daily life
    • Recurrent hospitalizations despite GDMT

    Also include NYHA functional classification:

    • Class I: No limitation
    • Class II: Slight limitation, symptoms with ordinary activity
    • Class III: Marked limitation, symptoms with less than ordinary activity
    • Class IV: Symptoms at rest

    2. DIAGNOSTICS

    Initial workup:

    • History and physical exam
    • ECG
    • Chest X-ray
    • Lab work: CBC, CMP, lipid panel, TSH, iron studies, BNP/NT-proBNP
    • Echocardiography (TTE) - cornerstone

    I'll expand the diagnostic approach with advanced imaging and specialized tests. These additional diagnostic tools help uncover the underlying etiology and assess disease complexity. Coronary evaluation becomes crucial to rule out ischemic causes, while cardiac MRI provides detailed tissue characterization. Genetic testing can reveal inherited cardiomyopathies, and specialized nuclear imaging techniques offer insights into myocardial viability and specific pathological processes.

    Key diagnostic strategies include comprehensive imaging and specialized testing to precisely characterize heart failure's underlying mechanisms and guide targeted treatment strategies.

    For heart failure diagnosis, BNP biomarkers serve as critical indicators, with specific thresholds signaling potential cardiac dysfunction across different clinical scenarios.

    Guideline-directed medical therapy (GDMT) represents the cornerstone of heart failure management, particularly for reduced ejection fraction. Four fundamental pharmacological interventions form the core treatment strategy:

    1. Neurohormonal modulators (ARNi/ACEi/ARB)
    2. Beta-blockers
    3. Mineralocorticoid receptor antagonists
    4. SGLT2 inhibitors

    Sacubitril/Valsartan emerges as the preferred neurohormonal agent, with carefully structured dosing protocols emphasizing gradual titration and close monitoring.

    Alternative pharmacological approaches include ACE inhibitors and ARBs, tailored for patients unable to tolerate primary treatments. Specific medications like lisinopril, enalapril, and ramipril offer structured dosing strategies, enabling systematic cardiac management.

    Dosing strategies prioritize gradual introduction and systematic dose escalation, ensuring patient safety and therapeutic effectiveness.

    Beta-Blockers demonstrate nuanced administration protocols:

    Carvedilol: Initiates at minimal 3.125 mg twice daily, progressively increasing to 25-50 mg based on patient weight, with careful two-week interval adjustments.

    Metoprolol Succinate: Begins at conservative 12.5-25 mg daily, targeting maximum 200 mg daily tolerance through incremental two-week progressions.

    Bisoprolol: Commences at 1.25 mg daily, methodically advancing to 10 mg daily using measured two-week incrementation.

    Mineralocorticoid Receptor Antagonists like spironolactone introduce modest 12.5-25 mg daily dosing, ultimately stabilizing at 25-50 mg to optimize therapeutic intervention.

    Eplerenone follows similar conservative initiation, starting at 25 mg daily and targeting 50 mg daily. Rigorous monitoring of potassium and renal function remains critical, with strict contraindications for elevated potassium or compromised kidney function.

    SGLT2 Inhibitors offer straightforward dosing: dapagliflozin and empagliflozin maintain consistent 10 mg daily administration, demonstrating remarkable efficacy even with reduced kidney function.

    For Black patients with heart failure, the A-HeFT protocol introduces a targeted combination of hydralazine and isosorbide dinitrate, specifically designed for those unable to tolerate standard medications. The regimen begins with a fixed dose and progressively increases to optimize cardiovascular management.

    Ivabradine provides precise heart rate control, initiating at 5 mg twice daily and carefully titrating to achieve an ideal 50-60 beats per minute range. Age-based dosing modifications ensure personalized treatment.

    Digoxin serves a nuanced role in symptom management, particularly for atrial fibrillation, with minimal dosing starting at 0.125 mg daily.

    The target serum level ranges between 0.5-0.9 ng/mL, ensuring therapeutic effectiveness while minimizing toxicity risks.

    Vericiguat emerges as a strategic intervention for patients with recent heart failure hospitalizations, employing a gradual dose escalation protocol that doubles every two weeks.

    Diuretic management focuses on flexible strategies, utilizing loop and thiazide diuretics to address fluid congestion and resistance.

    Fundamental titration principles emphasize cautious, incremental medication adjustments, prioritizing patient tolerance and closely monitoring physiological responses.

    Device Therapy Considerations

    ICD Placement Criteria:

    • Primary prevention targets patients with persistent low ejection fraction
    • Requires comprehensive cardiac functional assessment
    • Considers long-term survival potential and cardiac stability
    • Specific timing requirements post-cardiac events

    Secondary Prevention Scenarios:

    • Indicated for patients experiencing life-threatening arrhythmic events
    • Focuses on preventing recurrent dangerous cardiac rhythms

    Cardiac Resynchronization Therapy:

    • Recommended for patients with significant electrical conduction abnormalities
    • Requires specific cardiac structural and electrical parameters
    • Aims to improve cardiac synchronization and overall heart function

    Additional Device Interventions:

    • Temporary protective strategies for high-risk cardiac patients
    • Includes wearable monitoring and mechanical circulatory support
    • Bridges critical periods in cardiac treatment progression

    Heart Transplantation Criteria:

    • Advanced heart failure patients meeting specific clinical thresholds
    • Strict selection based on physiological and age-related factors
    • Comprehensive evaluation excluding medical contraindications

    Comprehensive Patient Management

    Targeted Diagnostic Assessments:

    • Systematic screening for iron metabolism markers
    • Precise diagnostic criteria for iron deficiency
    • Intravenous supplementation for symptomatic patients

    Cardiac Rhythm Management:

    • Multifaceted approach to atrial fibrillation
    • Strategic rate and rhythm control strategies
    • Interventional options for complex cardiac arrhythmias

    Metabolic Disease Considerations:

    • Prioritize SGLT2 inhibitors for diabetic heart failure patients
    • Emphasize cardiovascular protective medications
    • Carefully exclude potentially harmful diabetes treatments
    • Maintain metabolic control with judicious medication selection

    Renal Function Preservation:

    • Optimize heart failure guideline-directed medical therapy
    • Proactively manage kidney disease progression
    • Carefully monitor electrolyte and medication interactions
    • Address diuretic responsiveness challenges

    Blood Pressure Optimization:

    • Implement aggressive cardiovascular risk reduction
    • Target precise blood pressure management

    Heart Failure Management:

    • Comprehensive medication strategy
    • Screen for concurrent respiratory disorders
    • Address psychological comorbidities
    • Evaluate cardiac structural abnormalities
    • Manage electrolyte imbalances strategically

    Decompensation Management:

    • Assess patient's hemodynamic profile carefully
    • Categorize clinical presentation precisely
    • Implement targeted intervention protocols
    • Utilize advanced monitoring techniques
    • Customize treatment based on specific physiological state

    Diuretic Approach:

    • Individualize fluid management
    • Monitor response meticulously
    • Adjust dosing dynamically
    • Prevent electrolyte disruptions
    • Balance volume reduction with organ perfusion

    Pharmacological Considerations:

    • Optimize medication interactions
    • Mitigate potential adverse effects
    • Ensure safe continuation of critical therapies
    • Leverage potassium management strategies
    • Select interventions matching clinical profile

    Advanced Management Techniques:

    • Consider combination diuretic strategies
    • Explore alternative fluid removal methods
    • Utilize biomarker-guided therapeutic decisions
    • Implement precise hemodynamic interventions
    • Balance aggressive management with patient tolerance

    Vasodilators:

    • Nitroprusside: Carefully titrate 0.3-5 mcg/kg/min, vigilant for potential cyanide toxicity

    Inotropic Support:

    I'll strategically select agents to optimize cardiac performance:

    Dobutamine: Enhances cardiac output while reducing ventricular filling pressures, dosing from 2.5-20 mcg/kg/min.

    Milrinone: Precise dosing with potential load of 50 mcg/kg, maintenance at 0.25-0.75 mcg/kg/min, adjusting for renal function.

    Dopamine: Tiered approach based on dosage:

    • Low dose: Renal effects (debated)
    • Medium dose: Inotropic support
    • High dose: Vasopressor properties

    Medication Management During Acute Decompensation:

    I'll carefully modulate chronic medications:

    • Beta-blockers: Continue, potentially halving dose
    • ACEi/ARB/ARNI: Adjust or suspend if hypotensive
    • SGLT2i: Temporary discontinuation may be necessary

    Discharge Preparation:

    My focus shifts to comprehensive patient stabilization:

    • Transition to oral diuretics
    • Optimize guideline-directed medical therapy
    • Assess weight and symptoms
    • Provide patient education
    • Schedule early follow-up within one week

    Cardiogenic Shock Management:

    Critical hemodynamic targets and interventions:

    • Maintain mean arterial pressure ≥65 mmHg
    • Utilize inotropes/vasopressors
    • Consider mechanical circulatory support options
    • Engage specialized shock/advanced heart failure team

    Follow-Up Strategy:

    Systematic monitoring ensures optimal recovery:

    • Medication titration every 2-4 weeks
    • Stable patients: Quarterly assessments
    • Comprehensive evaluation at each visit
    • Targeted laboratory monitoring
    • Strategic echocardiographic reassessment

    Advanced Heart Failure Management:

    Critical referral triggers include:

    • Repeated hospitalizations
    • Continuous inotrope requirement
    • Persistent severe functional limitations
    • Potential advanced intervention candidacy

    Patient Self-Management:

    Key lifestyle modifications:

    • Strict dietary sodium control
    • Precise fluid intake management
    • Regular weight tracking
    • Proactive symptom surveillance
    • Medication compliance
    • Structured exercise program
    • Medication interaction awareness

    Preventive Care:

    Comprehensive immunization approach:

    • Annual influenza vaccination
    • Comprehensive pneumococcal protection
    • COVID-19 immunization protocol

    Rehabilitation Focus:

    Cardiac recovery priorities:

    • Structured rehabilitation program
    • Functional capacity enhancement
    • Evidence-based intervention strategy

    Holistic Care Approach:

    Comprehensive support considerations:

    • Early palliative care integration
    • Proactive end-of-life discussions
    • Advanced directive planning
    • Device management conversations # Comprehensive Guideline-Based Approach to HFrEF

    1. STAGING & CLASSIFICATION

    ACC/AHA Stages (2022)

    StageDefinitionKey Features
    AAt-RiskHTN, DM, CAD, obesity, cardiotoxin exposure, family hx of CM; no structural disease
    BPre-HFStructural disease (↓EF, LVH, WMA, valvular), elevated filling pressures; no symptoms
    CSymptomatic HFStructural disease with current or prior HF symptoms
    DAdvanced HFRefractory symptoms despite maximal GDMT; recurrent hospitalizations

    NYHA Functional Classification

    ClassLimitationDescription
    INoneNo symptoms with ordinary activity
    IISlightSymptoms with ordinary activity
    IIIMarkedSymptoms with less than ordinary activity
    IVSevereSymptoms at rest

    EF-Based Classification

    • HFrEF: LVEF ≤40%
    • HFmrEF: LVEF 41-49%
    • HFimpEF: Previously ≤40%, now >40%
    • HFpEF: LVEF ≥50%

    2. DIAGNOSTIC EVALUATION

    Initial Workup (All Patients)

    CategoryTests
    LabsCBC, CMP, glucose, lipids, TSH, iron studies (ferritin, TSAT), urinalysis
    BiomarkersBNP or NT-proBNP
    ImagingTTE (cornerstone), CXR
    ECGRhythm, conduction, QRS duration/morphology

    Natriuretic Peptide Thresholds

    SettingBNPNT-proBNP
    Chronic HF unlikely<35 pg/mL<125 pg/mL
    Acute HF unlikely<100 pg/mL<300 pg/mL (age-adjusted)*

    *Age-adjusted NT-proBNP: <450 (age <50), <900 (50-75), <1800 (>75)

    Etiology Workup

    CORONARY ASSESSMENT:
    ├── Coronary angiography (preferred if high CAD probability)
    ├── CCTA (intermediate probability)
    └── Stress testing with imaging
    
    ADVANCED IMAGING:
    ├── Cardiac MRI: Etiology, viability, scar characterization
    ├── PET: Viability, sarcoidosis
    └── PYP scan: Cardiac amyloidosis (ATTR)
    
    INVASIVE ASSESSMENT:
    ├── Right heart catheterization: Hemodynamics, PH evaluation
    └── Endomyocardial biopsy: Myocarditis, infiltrative disease
    
    GENETIC TESTING:
    └── When familial/heritable CM suspected
    

    3. GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT)

    The Four Pillars of HFrEF Therapy

    Current Approach: Initiate all four drug classes early, often simultaneously at low doses, rather than sequential titration

                        ┌─────────────────────────────────────────────┐
                        │        HFrEF (LVEF ≤40%)                    │
                        │   All 4 Pillars - Class I Recommendation    │
                        └─────────────────────────────────────────────┘
                                            │
            ┌───────────────┬───────────────┼───────────────┬───────────────┐
            ▼               ▼               ▼               ▼               
       ┌─────────┐     ┌─────────┐     ┌─────────┐     ┌─────────┐
       │  ARNI   │     │ β-Blocker│    │   MRA   │     │ SGLT2i  │
       │(or ACEi)│     │         │     │         │     │         │
       └─────────┘     └─────────┘     └─────────┘     └─────────┘
    

    PILLAR 1: ARNI/ACEi/ARB

    Sacubitril-Valsartan (Entresto) - PREFERRED

    ParameterRecommendation
    Starting Dose24/26 mg BID (ACEi-naive) or 49/51 mg BID (tolerating ACEi/ARB)
    Target Dose97/103 mg BID
    TitrationDouble every 2-4 weeks as tolerated
    Key Precaution36-hour washout from ACEi required
    ContraindicationsAngioedema history, pregnancy, eGFR <30, K+ >5.4

    ACE Inhibitors (if ARNI unavailable/not tolerated)

    DrugStarting DoseTarget Dose
    Lisinopril2.5-5 mg daily20-40 mg daily
    Enalapril2.5 mg BID10-20 mg BID
    Ramipril1.25-2.5 mg daily10 mg daily
    Captopril6.25 mg TID50 mg TID

    ARBs (if ACEi-intolerant due to cough)

    DrugStarting DoseTarget Dose
    Valsartan40 mg BID160 mg BID
    Losartan25-50 mg daily150 mg daily
    Candesartan4-8 mg daily32 mg daily

    PILLAR 2: Evidence-Based Beta-Blockers

    DrugStarting DoseTarget DoseTitration
    Carvedilol3.125 mg BID25 mg BID (≤85 kg) / 50 mg BID (>85 kg)Double q2 weeks
    Metoprolol succinate12.5-25 mg daily200 mg dailyIncrease q2 weeks
    Bisoprolol1.25 mg daily10 mg dailyIncrease q2 weeks

    ⚠️ Only these 3 beta-blockers have mortality benefit in HFrEF

    Initiation considerations:

    • Can initiate in stable, euvolemic patients
    • Reduce dose by 50% (don't stop) during decompensation
    • HR target: 50-70 bpm in sinus rhythm

    PILLAR 3: Mineralocorticoid Receptor Antagonists (MRA)

    DrugStarting DoseTarget Dose
    Spironolactone12.5-25 mg daily25-50 mg daily
    Eplerenone25 mg daily50 mg daily

    Eligibility & Monitoring:

    • K+ <5.0 mEq/L, eGFR ≥30 mL/min
    • Check K+ and Cr at 1 week, 1 month, then every 3 months
    • Hold if K+ >5.5 mEq/L

    PILLAR 4: SGLT2 Inhibitors

    DrugDoseMinimum eGFR
    Dapagliflozin10 mg daily20-25 mL/min
    Empagliflozin10 mg daily20 mL/min

    Key Points:

    • No titration needed
    • Works regardless of diabetes status
    • Continue until dialysis/transplant
    • Expect initial ↓eGFR (hemodynamic, non-progressive)
    • Hold during acute illness/procedures (sick day rules)

    Additional Therapies

    Hydralazine + Isosorbide Dinitrate (A-HeFT)

    IndicationStarting DoseTarget Dose
    Black patients on optimal GDMT37.5 mg/20 mg TID75 mg/40 mg TID
    ACEi/ARB/ARNI intolerant (any race)SameSame

    Ivabradine (Corlanor)

    CriteriaDosing
    Sinus rhythm, HR ≥70 bpm on max beta-blockerStart: 5 mg BID (2.5 mg if >75 years)
    Target: 7.5 mg BIDGoal HR: 50-60 bpm

    Vericiguat (Verquvo) - sGC Stimulator

    IndicationDosing
    Recent HF hospitalization or IV diuretic needStart: 2.5 mg daily
    High-risk patients on optimal GDMTTarget: 10 mg daily (double q2 weeks)

    Digoxin

    UseTarget Level
    Symptom control, AF rate control0.5-0.9 ng/mL
    Dose: 0.125 mg dailyReduce in elderly, renal impairment

    Diuretics (Symptomatic Relief)

    DrugBioavailabilityPO EquivalentIV Equivalent
    Furosemide40-80% (variable)40 mg20 mg
    Bumetanide80-100%1 mg1 mg
    Torsemide80-100%20 mg20 mg

    GDMT Titration Protocol

    WEEK 0: Initiate all 4 pillars at low doses (if hemodynamically stable)
       │
    WEEK 1-2: Labs (BMP) - assess tolerability
       │
    WEEK 2-4: First up-titration (prioritize as tolerated)
       │
    WEEK 4-8: Continue up-titration every 2-4 weeks
       │
    WEEK 8-12: Approach target doses
       │
    Month 3-6: Reassess EF for device eligibility
    

    Titration Priorities:

    1. Beta-blocker (if HR elevated)
    2. ARNI/ACEi (if BP allows)
    3. MRA (add when tolerating other RAAS inhibitor)
    4. SGLT2i (can add anytime)

    Acceptable Trade-offs:

    • Asymptomatic hypotension: Continue if SBP ≥90
    • Creatinine rise ≤30%: Continue therapy
    • K+ 5.0-5.5: Reduce MRA dose, monitor closely

    4. DEVICE THERAPY

    ICD (Implantable Cardioverter-Defibrillator)

    Primary Prevention

    CriteriaClass
    LVEF ≤35% + NYHA II-III on ≥3 months GDMT + survival >1 yearI
    LVEF ≤30% + NYHA I ischemic CM, ≥40 days post-MIIIa
    LVEF ≤35%, ≥90 days post-revascularizationI
    Non-ischemic CM: Reassess after 3-6 months optimal GDMTI

    Secondary Prevention

    CriteriaClass
    Survived VF arrest, not due to reversible causeI
    Sustained VT with hemodynamic instabilityI
    Sustained VT with LVEF ≤40%I

    Wearable Defibrillator (LifeVest)

    • Bridge during waiting period post-MI or revascularization
    • Newly diagnosed non-ischemic CM pending GDMT optimization
    • Post-device explant for infection

    CRT (Cardiac Resynchronization Therapy)

    QRS DurationQRS MorphologyLVEFSRRecommendation
    ≥150 msLBBB≤35%YesClass I
    130-149 msLBBB≤35%YesClass IIa
    ≥150 msNon-LBBB≤35%YesClass IIa
    130-149 msNon-LBBB≤35%YesClass IIb
    N/ARV pacing >40%≤35%AnyClass I (upgrade)

    CRT-D vs CRT-P:

    • CRT-D: Standard for most HFrEF patients meeting ICD + CRT criteria
    • CRT-P: May consider in elderly, significant comorbidities, limited life expectancy

    Advanced Heart Failure Therapies

    TherapyIndicationConsideration
    LVADBridge to transplant or destination therapyINTERMACS profiles 1-4
    Heart TransplantStage D, refractory to all therapiesAge typically <70, no absolute contraindications

    Referral Triggers for Advanced HF Evaluation:

    • ≥2 HF hospitalizations in 12 months
    • Persistent NYHA IV symptoms
    • Inotrope dependence
    • Peak VO₂ <14 mL/kg/min
    • Need for continuous hemodynamic support

    5. COMORBIDITY MANAGEMENT

    Iron Deficiency

    ParameterDefinitionTreatment
    Iron deficiencyFerritin <100 OR Ferritin 100-299 + TSAT <20%IV Iron
    Preferred agentsFerric carboxymaltose, Iron sucroseClass IIa
    Benefit↑ Functional capacity, ↓ HF hospitalizations

    Atrial Fibrillation

    TreatmentRecommendation
    AnticoagulationDOACs preferred; CHA₂DS₂-VASc guided
    Rate controlBeta-blockers, digoxin; avoid non-DHP CCBs
    Rhythm controlAmiodarone, dofetilide (hospital initiation)
    Catheter ablationClass IIa for symptomatic AF in HFrEF

    Diabetes Management

    Drug ClassRecommendation
    SGLT2 inhibitorsFirst-line with HFrEF (regardless of DM)
    GLP-1 RAsCV benefit; may reduce HF hospitalization
    MetforminSafe in stable HF; hold in decompensation
    TZDsAVOID - worsen HF
    InsulinUse if needed; may cause fluid retention

    Other Comorbidities

    ConditionManagement
    CKDContinue GDMT (accept Cr ↑30%); SGLT2i beneficial
    OSACPAP indicated
    CSAOptimize HF; avoid ASV (SERVE-HF)
    DepressionScreen; SSRIs safe; avoid TCAs
    HyperkalemiaPotassium binders (patiromer, SZC) to maintain RAAS inhibition
    GoutContinue allopurinol; avoid NSAIDs

    Valvular Heart Disease

    ValveTherapy
    Secondary MRMitraClip (COAPT criteria): EROA ≥30 mm², EF 20-50%, on optimal GDMT
    ASTAVR/SAVR per guidelines

    6. ACUTE DECOMPENSATED HF (ADHF) PROTOCOLS

    Hemodynamic Profiles

                        CONGESTION
                        ┌───────────────────────────────┐
                        │   YES              NO         │
            ┌───────────┼───────────────────────────────┤
         YES│   WARM-WET         WARM-DRY              │
            │   (most common)    (compensated)          │ PERFUSION
         NO │   COLD-WET         COLD-DRY              │
            │   (worst prognosis) (reassess volume)    │
            └───────────────────────────────────────────┘
    

    Treatment by Profile

    ProfileTreatment
    Warm-WetIV diuretics ± vasodilators
    Cold-WetInotropes + diuretics; invasive monitoring
    Cold-DryCareful volume assessment; inotropes if truly low output

    Diuretic Protocol

    Initial Dosing

    Diuretic StatusInitial IV Dose
    Diuretic-naiveFurosemide 20-40 mg IV
    On home diuretic1-2.5× oral dose as IV
    Severe congestionHigher initial doses

    Dose Escalation

    HOUR 0: Initial IV diuretic dose
       │
    HOUR 2-6: Assess response (UOP goal >100-150 mL/hr)
       │
    IF INADEQUATE:
    ├── Double the dose (up to 200-400 mg furosemide)
    ├── Add thiazide diuretic
    │   ├── Metolazone 2.5-10 mg PO (30 min before loop)
    │   └── Chlorothiazide 500-1000 mg IV
    ├── Add acetazolamide 500 mg IV daily (ADVOR trial)
    └── Consider ultrafiltration
    

    Targets

    • Net negative 1-3 L/day (or 3-5 L if severely congested)
    • Daily weight loss 0.5-1 kg
    • Symptom improvement
    • Near euvolemia at discharge

    Vasodilators

    DrugStarting DoseTitrationIndication
    Nitroglycerin10-20 mcg/minUp to 200 mcg/minSBP >100, pulmonary congestion
    Nitroprusside0.3 mcg/kg/minUp to 5 mcg/kg/minHypertensive emergency, severe MR

    Inotropes

    DrugDoseMechanismConsideration
    Dobutamine2.5-20 mcg/kg/minβ1 agonistFirst-line; may ↑ HR, arrhythmias
    Milrinone0.25-0.75 mcg/kg/minPDE3 inhibitorGreater vasodilation; reduce in CKD
    Dopamine3-10 mcg/kg/minDose-dependentInotropic at mid-doses

    Cardiogenic Shock

    RECOGNITION:
    • SBP <90 mmHg sustained or vasopressor requirement
    • End-organ hypoperfusion (lactate ↑, renal failure, altered mental status)
    • CI <2.2 L/min/m², PCWP >15
    
    MANAGEMENT:
    ├── MAP goal ≥65 mmHg
    ├── Vasopressors: Norepinephrine first-line
    ├── Inotropes: Dobutamine, milrinone
    ├── Mechanical support:
    │   ├── IABP (older technology)
    │   ├── Impella (percutaneous LVAD)
    │   └── VA-ECMO (biventricular/respiratory failure)
    └── Consult: Shock Team / Advanced HF
    

    GDMT During Hospitalization

    Drug ClassRecommendation
    Beta-blockersContinue (↓ dose by 50% if hypotensive); don't stop abruptly
    ARNI/ACEi/ARBMay hold if hypotensive, AKI; restart before discharge
    MRAHold if hyperkalemia or severe AKI
    SGLT2iMay hold briefly; restart when stable
    DiureticsOptimize before discharge

    Discharge Checklist

    • Euvolemia achieved (or clear plan)
    • GDMT optimized (or uptitrated)
    • Oral diuretic regimen established
    • Discharge weight documented
    • Warning signs education completed
    • Follow-up within 7 days scheduled
    • ACEi→ARNI transition if applicable
    • Consider initiating SGLT2i if not already on

    7. FOLLOW-UP & MONITORING

    Visit Schedule

    PhaseFrequencyFocus
    Post-dischargeWithin 7 days (Class I)Volume status, medication review
    GDMT titrationEvery 2-4 weeksUp-titration, tolerability
    StableEvery 3-6 monthsSymptoms, adherence, labs
    Advanced HFMonthly or moreClose monitoring, palliative care

    Laboratory Monitoring

    TestWhen
    BMP (K+, Cr)1-2 weeks after starting/↑ ACEi/ARB/ARNI/MRA
    BNP/NT-proBNPBaseline, with symptoms, ? serial monitoring
    CBCAnnually or with symptoms
    Iron studiesAnnually, or if anemia
    TSHAnnually (especially if on amiodarone)
    LFTsPeriodically if on statin, amiodarone

    Echocardiography

    TimingPurpose
    BaselineEstablish EF, structure
    3-6 months on GDMTReassess EF for device eligibility
    With clinical changeWorsening symptoms, new murmur
    Post CRT/revascularizationAssess response

    When to Refer to Advanced HF Specialist

    TriggerAction
    ≥2 HF hospitalizations/yearAdvanced HF evaluation
    Persistent NYHA III-IV on optimal therapyLVAD/transplant assessment
    Inotrope dependenceUrgent referral
    Peak VO₂ <14 mL/kg/minTransplant listing consideration
    Declining renal function limiting GDMTMultidisciplinary management

    Patient Education Essentials

    TopicGuidance
    Sodium<2000 mg/day (ideally <1500 mg)
    Fluid1.5-2 L/day if hyponatremic or refractory congestion
    Daily weightsSame time, same scale; report gain >1-2 kg/day or 2.5 kg/week
    MedicationsDo not stop abruptly; recognize side effects
    AvoidNSAIDs, certain OTC decongestants
    ActivityCardiac rehabilitation (Class I for stable HFrEF)

    Vaccines & Preventive Care

    VaccineSchedule
    InfluenzaAnnual
    PneumococcalPCV15/20 followed by PPSV23
    COVID-19Per current guidelines
    RSVConsider in high-risk adults

    Palliative Care Integration

    MilestoneDiscussion
    Stage D/Advanced HFGoals of care, symptom management
    Recurrent hospitalizationsPrognosis discussion
    Device decisionsICD deactivation preferences
    End of lifeHospice eligibility, comfort measures

    Summary: GDMT Target Doses at a Glance

    Drug ClassDrugTarget Dose
    ARNISacubitril/Valsartan97/103 mg BID
    ACEiLisinopril20-40 mg daily
    Enalapril10-20 mg BID
    ARBValsartan160 mg BID
    Losartan150 mg daily
    BBCarvedilol25 mg BID or 50 mg BID
    Metoprolol XL200 mg daily
    Bisoprolol10 mg daily
    MRASpironolactone25-50 mg daily
    Eplerenone50 mg daily
    SGLT2iDapagliflozin10 mg daily
    Empagliflozin10 mg daily
    H-ISDNHydralazine/Isosorbide75/40 mg TID
    If ChannelIvabradine7.5 mg BID
    sGCVericiguat10 mg daily

    This framework reflects 2022 ACC/AHA/HFSA and 2023 ESC guidelines. Individual patient factors always guide therapy decisions.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.